Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Vincenzo, Dadduzio"'
Autor:
Gennaro Gadaleta-Caldarola, Alessandro Rizzo, Vincenzo Dadduzio, Lucia Lombardi, Arianna Gadaleta-Caldarola, Stefania Infusino, Antonio Cusmai, Claudia Citrigno, Gennaro Palmiotti
Publikováno v:
Current Oncology, Vol 29, Iss 10, Pp 7925-7931 (2022)
Cholangiocarcinoma (CCA) is the second most frequent primary liver cancer, following hepatocellular carcinoma (HCC). Progress in the molecular understanding of CCA has led to the development of several agents, including FGFR inhibitors, such as pemig
Externí odkaz:
https://doaj.org/article/4fa626ba992f49b19c039aaaba1e5f5f
Autor:
Alessandro Rizzo, Vincenzo Dadduzio, Lucia Lombardi, Angela Dalia Ricci, Gennaro Gadaleta-Caldarola
Publikováno v:
Current Oncology, Vol 28, Iss 5, Pp 3393-3402 (2021)
Ampullary carcinomas (ACs) represent a rare entity, accounting for approximately 0.2% of all gastrointestinal solid tumors and 20% of all periampullary cancers (PACs). Unfortunately, few data are available regarding the optimal therapeutic strategy f
Externí odkaz:
https://doaj.org/article/a3ac9ac9a7c440cb99b9c5445e4faf79
Autor:
Francesco Tovoli, Vincenzo Dadduzio, Stefania De Lorenzo, Lorenza Rimassa, Gianluca Masi, Massimo Iavarone, Fabio Marra, Ingrid Garajova, Maria Pia Brizzi, Bruno Daniele, Franco Trevisani, Carlo Messina, Francesco Di Clemente, Sara Pini, Giuseppe Cabibbo, Alessandro Granito, Mario Domenico Rizzato, Vittorina Zagonel, Giovanni Brandi, Tiziana Pressiani, Piera Federico, Caterina Vivaldi, Irene Bergna, Claudia Campani, Fabio Piscaglia
Publikováno v:
Liver Cancer, Vol 10, Iss 4, Pp 370-379 (2021)
Introduction: Cabozantinib has been approved by the European Medicine Agency (EMA) for hepatocellular carcinoma (HCC) previously treated with sorafenib. Cabozantinib is also being tested in combination with immune checkpoint inhibitors in the frontli
Externí odkaz:
https://doaj.org/article/35465bb2f20d44ce85e4f6039cf0e079
Autor:
Francesco Caputo, Vincenzo Dadduzio, Francesco Tovoli, Giulia Bertolini, Giuseppe Cabibbo, Krisida Cerma, Caterina Vivaldi, Luca Faloppi, Mario Domenico Rizzato, Fabio Piscaglia, Ciro Celsa, Lorenzo Fornaro, Giorgia Marisi, Fabio Conti, Nicola Silvestris, Marianna Silletta, Sara Lonardi, Alessandro Granito, Caterina Stornello, Valentina Massa, Giorgio Astara, Sabina Delcuratolo, Stefano Cascinu, Mario Scartozzi, Andrea Casadei-Gardini
Publikováno v:
PLoS ONE, Vol 15, Iss 5, p e0232449 (2020)
BACKGROUND AND AIMS:The present study aims to investigate the role of the prognostic nutritional index (PNI) on survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. METHODS:This multicentric study included a train
Externí odkaz:
https://doaj.org/article/574a3b3c1a624653a2b3f7e78e7be113
Autor:
Ghassan K. Abou-Alfa, Anthony B. El-Khoueiry, Ann-Lii Cheng, Rajesh Kaldate, David W. Markby, Vincenzo Dadduzio, Albert Tran, Vincent C. Tam, Jean-Frederic Blanc, Stephen L. Chan, Thomas Yau, Joong-Won Park, Philippe Merle, Lorenza Rimassa, Tim Meyer, Robin Kate Kelley
Figure S1. Forest plots of overall survival and progression-free survival by baseline AFP. Hazard ratios are stratified for the overall study population and unstratified for the subgroups.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfc342b7ae22d37f2deef0717192ef0c
https://doi.org/10.1158/1078-0432.22475862
https://doi.org/10.1158/1078-0432.22475862
Autor:
Ghassan K. Abou-Alfa, Anthony B. El-Khoueiry, Ann-Lii Cheng, Rajesh Kaldate, David W. Markby, Vincenzo Dadduzio, Albert Tran, Vincent C. Tam, Jean-Frederic Blanc, Stephen L. Chan, Thomas Yau, Joong-Won Park, Philippe Merle, Lorenza Rimassa, Tim Meyer, Robin Kate Kelley
Purpose:The phase III CELESTIAL study demonstrated improved overall survival (OS) and progression-free survival (PFS) with cabozantinib versus placebo in patients with previously treated, advanced hepatocellular carcinoma (HCC). We analyzed outcomes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52683f429b0442e18b5c2c784e1943d2
https://doi.org/10.1158/1078-0432.c.6529197
https://doi.org/10.1158/1078-0432.c.6529197
Autor:
Ghassan K. Abou-Alfa, Anthony B. El-Khoueiry, Ann-Lii Cheng, Rajesh Kaldate, David W. Markby, Vincenzo Dadduzio, Albert Tran, Vincent C. Tam, Jean-Frederic Blanc, Stephen L. Chan, Thomas Yau, Joong-Won Park, Philippe Merle, Lorenza Rimassa, Tim Meyer, Robin Kate Kelley
Supplementary Data_Clean File
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1221a1d53068b1cc61d3e76c8e03eaf8
https://doi.org/10.1158/1078-0432.22475850.v1
https://doi.org/10.1158/1078-0432.22475850.v1
Autor:
Mario Scartozzi, Stefano Cascinu, Vittorina Zagonel, Giulia Rovesti, Giulia Orsi, Francesca Fornari, Sara Lonardi, Giovanni Gerardo Cardellino, Marianna Silletta, Nicola Silvestris, Lorenzo Fornaro, Britt Rudnas, Fabio Conti, Matteo Canale, Luca Ielasi, Mario Domenico Rizzato, Caterina Vivaldi, Emiliano Tamburini, Francesco Giuseppe Foschi, Paola Ulivi, Luca Faloppi, Laura Gramantieri, Vincenzo Dadduzio, Giorgia Marisi, Andrea Casadei-Gardini
All Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30bb3be0e92f5a8fb146421990a69d52
https://doi.org/10.1158/1078-0432.22477397
https://doi.org/10.1158/1078-0432.22477397
Autor:
Mario Scartozzi, Stefano Cascinu, Vittorina Zagonel, Giulia Rovesti, Giulia Orsi, Francesca Fornari, Sara Lonardi, Giovanni Gerardo Cardellino, Marianna Silletta, Nicola Silvestris, Lorenzo Fornaro, Britt Rudnas, Fabio Conti, Matteo Canale, Luca Ielasi, Mario Domenico Rizzato, Caterina Vivaldi, Emiliano Tamburini, Francesco Giuseppe Foschi, Paola Ulivi, Luca Faloppi, Laura Gramantieri, Vincenzo Dadduzio, Giorgia Marisi, Andrea Casadei-Gardini
Purpose:After 10 years of clinical practice and research studies, there are still no validated prognostic or predictive factors of response to sorafenib for hepatocellular carcinoma (HCC). On the basis of the results of our two retrospective studies,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::142c1dd3321e0a971ad47f8ee6633bb7
https://doi.org/10.1158/1078-0432.c.6529649.v1
https://doi.org/10.1158/1078-0432.c.6529649.v1
Autor:
Rodolfo Sacco, Daryl Ramai, Raffaella Tortora, Giovan Giuseppe di Costanzo, Michela Emma Burlone, Mario Pirisi, Piera Federico, Bruno Daniele, Marianna Silletta, Paolo Gallo, Caterina Cocuzza, Maurizio Russello, Giuseppe Cabibbo, Gabriele Rancatore, Silvia Cesario, Gianluca Masi, Luca Marzi, Andrea Mega, Alessandro Granito, Giulia Pieri, Edoardo G. Giannini, Rosa Paolillo, Gennaro Gadaleta-Caldarola, Vincenzo Dadduzio, Guido Giordano, Luca Giacomelli, Simonetta Papa, Matteo Renzulli, Marcello Maida, Michele Ghidini, Mauro Borzio, Antonio Facciorusso
Publikováno v:
Cancers; Volume 15; Issue 2; Pages: 381
Background: Whether the etiology of underlying liver disease represents a prognostic factor in patients with hepatocellular carcinoma (HCC) treated with lenvatinib is still a matter of debate. This study investigates whether the viral etiology of HCC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2edcc48c85be730c627250ec18255f9
https://hdl.handle.net/11585/918156
https://hdl.handle.net/11585/918156